RhumbLine Advisers’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-35,439
| Closed | -$993K | – | 3344 |
|
|
2022
Q1 | $993K | Buy |
35,439
+3,647
| +11% | +$99.9K | ﹤0.01% | 2133 |
|
|
2021
Q4 | $868K | Sell |
31,792
-6,112
| -16% | -$166K | ﹤0.01% | 2263 |
|
|
2021
Q3 | $1.03M | Buy |
37,904
+250
| +0.7% | +$6.18K | ﹤0.01% | 2217 |
|
|
2021
Q2 | $644K | Sell |
37,654
-2,930
| -7% | -$54.8K | ﹤0.01% | 2438 |
|
|
2021
Q1 | $847K | Sell |
40,584
-2,630
| -6% | -$60.7K | ﹤0.01% | 2263 |
|
|
2020
Q4 | $990K | Buy |
43,214
+1,915
| +5% | +$36.5K | ﹤0.01% | 2134 |
|
|
2020
Q3 | $674K | Sell |
41,299
-5,625
| -12% | -$102K | ﹤0.01% | 2156 |
|
|
2020
Q2 | $635K | Buy |
46,924
+3,936
| +9% | +$45.8K | ﹤0.01% | 2240 |
|
|
2020
Q1 | $509K | Buy |
42,988
+1,408
| +3% | +$31.2K | ﹤0.01% | 2156 |
|
|
2019
Q4 | $1.03M | Buy |
41,580
+388
| +0.9% | +$7.86K | ﹤0.01% | 2066 |
|
|
2019
Q3 | $701K | Buy |
41,192
+697
| +2% | +$12.7K | ﹤0.01% | 2198 |
|
|
2019
Q2 | $922K | Buy |
40,495
+1,277
| +3% | +$34.4K | ﹤0.01% | 2095 |
|
|
2019
Q1 | $1.26M | Sell |
39,218
-329
| -0.8% | -$10.2K | ﹤0.01% | 1927 |
|
|
2018
Q4 | $1.11M | Buy |
39,547
+12,700
| +47% | +$372K | ﹤0.01% | 1951 |
|
|
2018
Q3 | $772K | Sell |
26,847
-2,084
| -7% | -$62.6K | ﹤0.01% | 2108 |
|
|
2018
Q2 | $1.08M | Buy |
28,931
+4,030
| +16% | +$158K | ﹤0.01% | 1972 |
|
|
2018
Q1 | $979K | Sell |
24,901
-57
| -0.2% | -$2.08K | ﹤0.01% | 1951 |
|
|
2017
Q4 | $809K | Sell |
24,958
-4,763
| -16% | -$143K | ﹤0.01% | 2036 |
|
|
2017
Q3 | $926K | Buy |
29,721
+325
| +1% | +$9.62K | ﹤0.01% | 2016 |
|
|
2017
Q2 | $822K | Buy |
29,396
+1,625
| +6% | +$36.8K | ﹤0.01% | 2045 |
|
|
2017
Q1 | $476K | Buy |
27,771
+759
| +3% | +$10.6K | ﹤0.01% | 2277 |
|
|
2016
Q4 | $327K | Buy |
27,012
+4,241
| +19% | +$54.9K | ﹤0.01% | 2448 |
|
|
2016
Q3 | $361K | Buy |
22,771
+430
| +2% | +$6.48K | ﹤0.01% | 2381 |
|
|
2016
Q2 | $289K | Buy |
22,341
+7,048
| +46% | +$110K | ﹤0.01% | 2556 |
|
|
2016
Q1 | $291K | Buy |
15,293
+65
| +0.4% | +$1.18K | ﹤0.01% | 2542 |
|
|
2015
Q4 | $343K | Buy |
15,228
+1,700
| +13% | +$33.6K | ﹤0.01% | 2488 |
|
|
2015
Q3 | $317K | Buy |
13,528
+1,753
| +15% | +$48.4K | ﹤0.01% | 2498 |
|
|
2015
Q2 | $337K | Buy |
+11,775
| New | +$309K | ﹤0.01% | 2576 |
|
RhumbLine Advisers's XENT Position: Q2 2022 in Review
RhumbLine Advisers sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 35,439 shares — an estimated $993K sold.
RhumbLine Advisers first reported a position in XENT in Q2 2015 and held it in 28 quarters. The position peaked at $1.26M in Q1 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- RhumbLine Advisers reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- RhumbLine Advisers sold 35,439 Intersect ENT, Inc shares in Q2 2022, an estimated $993K.
- RhumbLine Advisers first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 28 quarters.
- RhumbLine Advisers's Intersect ENT, Inc position peaked at $1.26M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.